Sort
261,768 grants matching “gene therapy”
Targeting PD-1 Pathway for Functional Cure of AIDS
$869,526Rama Rao Amara · Emory University · R37 · FY2015 · AI
Sexual Development of Cryptosporidium
$869,492Boris Striepen · University Of Pennsylvania · R01 · FY2025 · AI
Neuroimmune pathways linking chronic psychosocial stress to co-occurring stimulant use and depression in HIV disease: a mechanistic clinical trial
$869,488Christina S Meade · Wake Forest University Health Sciences · R01 · FY2024 · DA
NP855 for Targeting Thyrointegrin αvβ3 receptors and Norepinephrine Transporter in Neuroblastoma Management
$869,433Paul Davis · Nanopharmaceuticals, Llc · R44 · FY2025 · CA
Development of 211Astatine-Conjugated Anti-CD45 Antibody-Based Conditioning for Hematopoietic Stem Cell Gene Therapy and Editing
$869,409Roland Bruno Walter · Fred Hutchinson Cancer Center · R01 · FY2022 · HL
Research Toward Occupational Safety in Vocalization
$869,314Denver Center For The Performing Arts · R01 · FY2005 · DC
The Molecular Profile of Prostate Tumors in African-American Men
$869,296Stefan Ambs · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Stress Management of Cryptococcal Pathogens
$869,294Kyung Kwon-Chung · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Preclinical Mouse Models of Thyroid Cancer
$869,240Sheue-Yann Cheng · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Impact of Interventions on Clonally Expanded Proviruses and Their RNA Expression
$869,203Mary Kearney · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
CCR-Frederick Flow Cytometry Core
$869,063Kathleen Noer · Division Of Basic Sciences - Nci · ZIC · FY2014 · CA
Epidural Current-Steering for Selective Modulation of Lower Urinary Tract Function
$869,043Bryan L McLaughlin · Micro-Leads, Inc. · OT2 · FY2020 · OD
Programming and Reprogramming Human Cells
$868,894Rudolf Jaenisch · Whitehead Institute For Biomedical Res · R01 · FY2009 · CA
Disordered Cellular Cholesterol Movement, Cell Death, and Multisystem Disease
$868,830Stephen Dean Turley · Ut Southwestern Medical Center · R01 · FY2012 · HL
Normal and Pathologic Functions of CTCF and Its Distinct Classes of DNA-targets
$868,802Victor Lobanenkov · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
Molecular Discovery for Optic Nerve Regeneration
$868,732Jeffrey L Goldberg · Stanford University · U01 · FY2016 · EY
Characterization of Persistent COVID-19
$868,661Jonathan Li · Brigham And Women'S Hospital · R01 · FY2023 · AI
Transcriptome resources for comparative primate models of lentivirus infection
$868,612Guido Silvestri · Emory University · R24 · FY2013 · OD
Routes to enhanced HIV neuropathogenesis through expression of subclinical levels of endogenous amyloid-beta
$868,544David J Volsky · Icahn School Of Medicine At Mount Sinai · R56 · FY2020 · NS
Development of a novel small molecule RPN13 inhibitor and therapeutic for advanced ovarian cancer patients
$868,417Ravi Kumar Anchoori · Up Therapeutics, Inc. · R44 · FY2023 · CA
Study on Thalidomide as BACE1 inhibitor in Alzhiemer's disease
$868,159Yong Shen · Banner Sun Health Research Institute · R01 · FY2009 · AG
NAD Augmentation to Treat Diabetic Kidney Disease: A Randomized Controlled Trial
$868,111Shalendar Bhasin · Brigham And Women'S Hospital · U01 · FY2023 · AG
THE GENETICS OF VULNERABILITY TO NICOTINE ADDICTIONS
$868,087Pamela Ann Madden · Washington University · R01 · FY2011 · DA
Mediators of Systemic Inflammation and Heart Failure Risk in the Community
$868,069Susan Cheng · Cedars-Sinai Medical Center · R01 · FY2019 · HL
Neuregulin-4: A Novel Therapy for Inflammatory Bowel Disease
$867,924Soumitra Ghosh · Avexegen Therapeutics, Inc. · R44 · FY2021 · DK